DEPOMED INC (DEPO) Stock Price & Overview
NASDAQ:DEPO • US2499081048
Current stock price
The current stock price of DEPO is 7.3 null. Today DEPO is up by 1.67%. In the past month the price decreased by -11.62%. In the past year, price increased by 11.45%.
DEPO Key Statistics
- Market Cap
- 466.616M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.48
- Dividend Yield
- N/A
DEPO Stock Performance
DEPO Stock Chart
DEPO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to DEPO. When comparing the yearly performance of all stocks, DEPO turns out to be only a medium performer in the overall market: it outperformed 58.26% of all stocks.
DEPO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DEPO. DEPO has a medium profitability rating, but doesn't score so well on its financial health evaluation.
DEPO Earnings
DEPO Forecast & Estimates
DEPO Financial Highlights
Over the last trailing twelve months DEPO reported a non-GAAP Earnings per Share(EPS) of -0.48000000000000004. The EPS increased by 13.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -9.52% | ||
| ROA | -3.98% | ||
| ROE | -19% | ||
| Debt/Equity | 1.03 |
DEPO Ownership
About DEPO
Company Profile
Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once- daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin XR extended-release tablets have been approved by the FDA for the once-daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once-daily Glumetza has been approved for use in adults with type two diabetes and is currently being marketed in the United States and Canada. The company is currently evaluating Gabapentin GR for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy, and menopausal hot flashes.
Company Info
DEPOMED INC
7999 GATEWAY BLVD. SUITE 300
NEWARK CA 94560
CEO: Arthur J. Higgins
Phone: 510-744-8000
DEPOMED INC / DEPO FAQ
What does DEPO do?
Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once- daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin XR extended-release tablets have been approved by the FDA for the once-daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once-daily Glumetza has been approved for use in adults with type two diabetes and is currently being marketed in the United States and Canada. The company is currently evaluating Gabapentin GR for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy, and menopausal hot flashes.
What is the stock price of DEPOMED INC today?
The current stock price of DEPO is 7.3 null. The price increased by 1.67% in the last trading session.
What is the dividend status of DEPOMED INC?
DEPO does not pay a dividend.
What is the ChartMill rating of DEPOMED INC stock?
DEPO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy DEPO stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DEPO.
Can you provide the market cap for DEPOMED INC?
DEPOMED INC (DEPO) has a market capitalization of 466.62M null. This makes DEPO a Small Cap stock.